查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1654325

全球标靶蛋白质降解市场：市场规模、份额、趋势分析（按类型、应用、最终用途和地区）、细分市场预测（2025-2030 年）

Targeted Protein Degradation Market Size, Share & Trends Analysis Report By Type (PROTAC, Molecular Glues), By Application (Drug Discovery, Therapy Development), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

标靶蛋白质降解市场趋势：

2024 年全球标靶蛋白质降解市场规模估计为 5.444 亿美元，预计 2025 年至 2030 年的复合年增长率为 20.80%。

癌症和神经退化性疾病等慢性病的发生率不断增加，以及生活方式的改变和医疗支出的增加，推动了市场的成长。这些疾病的高发性对新型治疗方案产生了强烈需求，推动了市场成长。

例如，根据世界卫生组织（WHO）的资料，2022年将诊断出约2,000万例新发癌症病例，并有970万人死于癌症。此外，估计有 5,350 万人在确诊癌症后五年内仍会罹患癌症。

该领域研发活动的扩大将提供巨大的市场成长机会。例如，2023 年 12 月，奥地利科学基金 (FWF)核准了靶向蛋白质降解 (SFB) 特别研究计划，第二个津贴期为四年。靶向蛋白质降解（SFB）特别研究计划是一项研究倡议，重点是了解和开发针对特定蛋白质进行细胞降解的方法。该计画旨在推动靶向蛋白质降解领域的发展，该领域近年来由于其在药物发现和治疗性介入的潜在应用而引起了广泛关注。

支持性法规环境，尤其是 FDA 和 EMA 等机构简化的核准流程，在加速采用基于 TPD 的治疗方法方面发挥关键作用。平台技术的快速进步正在推动靶向蛋白质降解行业的发展。蛋白水解靶向嵌合体(PROTAC)、分子黏合剂和溶酶体靶向嵌合体(LYTAC) 等创新方法的开发扩展了 TPD 选择性消除致病蛋白质的能力。这些技术突破为针对以前无法用药的蛋白质开闢了新的途径，推动了靶向蛋白质降解行业的成长。

人们越来越认识到标靶蛋白质降解对于解决以前无法治疗的疾病的治疗潜力，这是靶向蛋白质降解行业发展的主要驱动力。儘管传统方法经常难以处理难以调控的蛋白质，但 PROTAC（蛋白质降解靶向嵌合体）等技术透过促进致病蛋白质的降解提供了有利的解决方案。这种方法在治疗神经退化性疾病显示出巨大的潜力，从而引发该领域的研究和投资激增。美国国立卫生研究院已将PROTAC列为现代药物开发的旗舰技术。随着临床前和早期临床试验的成功率不断提高，製药和生物技术公司正在将标靶蛋白质降解整合到他们的产品线中，并认识到其改变治疗策略的潜力。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. 标靶蛋白质降解市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 目标蛋白质降解市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析
    • COVID-19影响分析

第 4 章 标靶蛋白质降解市场：按类型进行估计和趋势分析

  • 细分仪表板
  • 标靶蛋白质降解市场：按类型进行差异分析
  • 标靶蛋白质降解市场：市场规模预测与趋势分析（按类型）（2018-2030 年）
  • PROTAC
  • 分子黏合剂
  • LYTAC
  • 其他的

第 5 章 标靶蛋白质降解市场：按应用的估计和趋势分析

  • 细分仪表板
  • 标靶蛋白质降解市场：按应用进行的变化分析
  • 标靶蛋白质降解市场：按应用分類的市场规模预测和趋势分析（2018-2030 年）
  • 药物研发
  • 开发治疗方法
    • 癌症
    • 神经病学
    • 感染疾病
    • 心血管疾病
    • 其他的

第六章 标靶蛋白质降解市场：依最终用途的估计与趋势分析

  • 细分仪表板
  • 靶向蛋白质降解市场：按最终用途进行的变化分析
  • 标靶蛋白质降解市场：按最终用途分類的市场规模预测和趋势分析（2018-2030 年）
  • 製药和生物技术公司
  • 学术研究所
  • 医院和临床实验室

第七章靶向蛋白质降解市场：区域估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司/竞争对手分类
  • 战略地图
  • 企业市场分析（2024）
  • 公司简介/上市公司
    • Bayer AG
    • Bio-Techne
    • BOC Sciences
    • BPS Bioscience, Inc.
    • BroadPharm
    • LifeSensors Inc.
    • MedChemExpress.
    • Merck KGaA
    • Promega Corporation
    • Thermo Fisher Scientific, Inc.
Product Code: GVR-4-68040-351-3

Targeted Protein Degradation Market Trends:

The global targeted protein degradation market size was estimated at USD 544.4 million in 2024 and is projected to grow at a CAGR of 20.80% from 2025 to 2030. The constantly growing frequency of chronic disease conditions such as cancer and neurodegenerative diseases, along with changing lifestyles and increasing healthcare spending, are accelerating the market growth. The high prevalence of these diseases creates a strong demand for novel treatment options, driving market growth.

For instance, data from the World Health Organization (WHO) indicates that in 2022, around 20 million individuals were newly diagnosed with cancer, and there were 9.7 million cancer-related deaths. It's estimated that 53.5 million people were living with cancer within five years after receiving their diagnosis.

The expanding number of research and development activities in this field provides significant market growth opportunities. For instance, in December 2023, the Austrian Science Fund (FWF) approved the Special Research Program (SFB) in Targeted Protein Degradation for a second funding period of another four years. The SFB in Targeted protein degradation is a research initiative focusing on understanding and developing methods to target specific proteins for cell degradation. This program aims to advance the field of targeted protein degradation, which has gained significant attention in recent years due to its potential applications in drug discovery and therapeutic interventions.

The supportive regulatory environment, particularly the streamlined approval processes by agencies such as the FDA and EMA, has played a crucial role in accelerating the adoption of TPD-based therapies. Rapid advancements in the underlying technologies drive the targeted protein degradation industry. The development of innovative approaches, such as proteolysis-targeting chimeras (PROTACs), molecular glues, and lysosome-targeting chimeras (LYTACs), has expanded TPD's capabilities to eliminate disease-causing proteins selectively. These technological breakthroughs have opened up new avenues for targeting previously undruggable proteins, driving the growth of the targeted protein degradation industry.

The increasing recognition of the therapeutic potential of targeted protein degradation in addressing previously undruggable targets is a key driver for the targeted protein degradation industry. Traditional approaches often struggle with proteins that are difficult to modulate, but technologies such as PROTACs (proteolysis-targeting chimeras) provide a favorable solution by promoting the degradation of disease-causing proteins. This method has shown considerable promise in treating conditions such as cancer and neurodegenerative disorders, sparking a surge in research and investment in this area. The National Institute of Health highlights PROTACs as a leading drug development technology in recent years. The increasing success in preclinical and early-phase clinical trials drives pharmaceutical and biotech companies to integrate targeted protein degradation into their pipelines, recognizing its potential to transform therapeutic strategies.

Global Targeted Protein Degradation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global targeted protein degradation market report based on type, application, end-use, and region.

  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • PROTAC
  • Molecular Glues
  • LYTACs
  • Others
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Drug Discovery
  • Therapy Development
    • Cancer
    • Neurology
    • Infectious Diseases
    • Cardiovascular Diseases
    • Others
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Hospitals & Clinical Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Targeted Protein Degradation Market Variables & Trends

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing frequency of chronic diseases
      • 3.2.1.2. Research and development activities
      • 3.2.1.3. Increasing recognition of the therapeutic potential of targeted protein degradation
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost
      • 3.2.2.2. Stringent regulations associated with approvals for novel TPD based therapies
  • 3.3. Targeted Protein Degradation Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Targeted Protein Degradation Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Targeted Protein Degradation Market Type Movement Analysis
  • 4.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. PROTAC
    • 4.4.1. PROTAC market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Molecular Glues
    • 4.5.1. Molecular Glues market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. LYTACs
    • 4.6.1. LYTACs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Targeted Protein Degradation Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Targeted Protein Degradation Market Application Movement Analysis
  • 5.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Drug Discovery
    • 5.4.1. Drug Discovery market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Therapy Development
    • 5.5.1. Therapy Development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Cancer
      • 5.5.2.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. Neurology
      • 5.5.3.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Infectious Diseases
      • 5.5.4.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. Cardiovascular Diseases
      • 5.5.5.1. Cardiovascular Diseases market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.6. Others
      • 5.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Targeted Protein Degradation Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Targeted Protein Degradation Market End Use Movement Analysis
  • 6.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Academic & Research Institutes
    • 6.5.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Hospitals & Clinical Laboratories
    • 6.6.1. Hospitals & Clinical Laboratories market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Targeted Protein Degradation Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Target disease prevalence
      • 7.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Target disease prevalence
      • 7.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Target disease prevalence
      • 7.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Target disease prevalence
      • 7.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Target disease prevalence
      • 7.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Target disease prevalence
      • 7.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Target disease prevalence
      • 7.5.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Target disease prevalence
      • 7.5.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.9. Denmark
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Competitive scenario
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Target disease prevalence
      • 7.5.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Target disease prevalence
      • 7.6.7.4. Regulatory framework
      • 7.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Target disease prevalence
      • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Target disease prevalence
      • 7.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Competitive scenario
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Target disease prevalence
      • 7.8.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Bayer AG
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Type benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Bio-Techne
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Type benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. BOC Sciences
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Type benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. BPS Bioscience, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Type benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. BroadPharm
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Type benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. LifeSensors Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Type benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. MedChemExpress.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Type benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Merck KGaA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Type benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Promega Corporation
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Type benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Thermo Fisher Scientific, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Type benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global Targeted protein degradation market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 4 Global Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 8 North America Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Canada Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 14 Canada Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Mexico Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 17 Mexico Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 21 Europe Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 24 Germany Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 UK Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 27 UK Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 France Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 30 France Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 31 France Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Italy Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 33 Italy Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Spain Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 36 Spain Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Denmark Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 39 Denmark Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Sweden Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 42 Sweden Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Norway Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 45 Norway Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 China Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 52 China Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 53 China Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Japan Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 55 Japan Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 India Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 58 India Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 59 India Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 South Korea Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 61 South Korea Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Australia Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 64 Australia Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Thailand Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 67 Thailand Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 71 Latin America Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Brazil Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 74 Brazil Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 79 MEA Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 81 MEA Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Africa Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 90 UAE Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Targeted Protein Degradation market: Market outlook
  • Fig. 5 Targeted Protein Degradation market: Segment outlook
  • Fig. 6 Targeted Protein Degradation market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Targeted Protein Degradation market driver impact
  • Fig. 9 Targeted Protein Degradation market restraint impact
  • Fig. 10 Targeted Protein Degradation market: Type outlook and key takeaways
  • Fig. 11 Targeted Protein Degradation market: Type movement analysis
  • Fig. 12 PROTAC market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Molecular Glues market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 LYTACs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Targeted Protein Degradation market: Application outlook and key takeaways
  • Fig. 17 Targeted Protein Degradation market: Application movement analysis
  • Fig. 18 Drug Discovery market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Therapy Development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Infectious Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Cardiovascular Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Targeted Protein Degradation market: End Use outlook and key takeaways
  • Fig. 26 Targeted Protein Degradation market: End Use movement analysis
  • Fig. 27 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 28 Academic & Research Institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Hospitals & Clinical Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Global Targeted Protein Degradation market: Regional outlook and key takeaways
  • Fig. 32 Global Targeted Protein Degradation market: Regional movement analysis
  • Fig. 33 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Target Disease Prevalence
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Target Disease Prevalence
  • Fig. 40 Key country dynamics
  • Fig. 41 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Target Disease Prevalence
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Target Disease Prevalence
  • Fig. 47 Key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Target Disease Prevalence
  • Fig. 50 Key country dynamics
  • Fig. 51 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Target Disease Prevalence
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Target Disease Prevalence
  • Fig. 56 Key country dynamics
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Target Disease Prevalence
  • Fig. 59 Key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Target Disease Prevalence
  • Fig. 62 Key country dynamics
  • Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Target Disease Prevalence
  • Fig. 65 Key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Target Disease Prevalence
  • Fig. 68 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Target Disease Prevalence
  • Fig. 72 Key country dynamics
  • Fig. 73 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Target Disease Prevalence
  • Fig. 75 Key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Target Disease Prevalence
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Target Disease Prevalence
  • Fig. 81 Key country dynamics
  • Fig. 82 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Target Disease Prevalence
  • Fig. 84 Key country dynamics
  • Fig. 85 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Target Disease Prevalence
  • Fig. 87 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Target Disease Prevalence
  • Fig. 91 Key country dynamics
  • Fig. 92 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Target Disease Prevalence
  • Fig. 94 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Target Disease Prevalence
  • Fig. 98 Key country dynamics
  • Fig. 99 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Target Disease Prevalence
  • Fig. 101 Key country dynamics
  • Fig. 102 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Target Disease Prevalence
  • Fig. 104 Key country dynamics
  • Fig. 105 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Target Disease Prevalence